Combined Biomarker Analysis for Risk of Acute Kidney Injury in Patients with ST-Segment Elevation Myocardial Infarction

Ying-Chang Tung¹, Chih-Hsiang Chang², Yung-Chang Chen², Pao-Hsien Chu¹,²,³,⁴*¹

¹ Department of Cardiology, Chang Gung Memorial Hospital, Taipei, Taiwan, ² Department of Nephrology, Chang Gung Memorial Hospital, Taipei, Taiwan, ³ Healthcare Center, Chang Gung Memorial Hospital, Taipei, Taiwan, ⁴ Chang Gung University College of Medicine, Taipei, Taiwan

* pchu@adm.cgmh.org.tw

Abstract

Background
Acute kidney injury (AKI) complicating ST-segment elevation myocardial infarction (STEMI) increases subsequent morbidity and mortality. We combined the biomarkers of heart failure (HF; B-type natriuretic peptide [BNP] and soluble ST2 [sST2]) and renal injury (NGAL [neutrophil gelatinase-associated lipocalin] and cystatin C) in predicting the development of AKI in patients with STEMI undergoing primary percutaneous coronary intervention (PCI).

Methods and Results
From March 2010 to September 2013, 189 STEMI patients were sequentially enrolled and serum samples were collected at presentation for BNP, sST2, NGAL and cystatin C analysis. 37 patients (19.6%) developed AKI of varying severity within 48 hours of presentation. Uni-variate analysis showed age, Killip class/C21², hypertension, white blood cell counts, hemoglobin, estimated glomerular filtration rate, blood urea nitrogen, creatinine, and all the four biomarkers were predictive of AKI. Serum levels of the biomarkers were correlated with risk of AKI and the Acute Kidney Injury Network (AKIN) stage and all significantly discriminated AKI (area under the receiver operating characteristic [ROC] curve: BNP: 0.86, sST2: 0.74, NGAL: 0.75, cystatin C: 0.73; all P<0.05). Elevation of/C21² of the biomarkers higher than the cutoff values derived from the ROC analysis improved AKI risk stratification, regardless of the creatine level (creatinine/C21<1.24 mg/dL: odds ratio [OR] 11.25, 95% confidence interval [CI] 1.63-77.92, P = 0.014; creatinine/C21≥1.24: OR 15.0, 95% CI 1.23-183.6, P = 0.034).

Conclusions
In this study of STEMI patients undergoing primary PCI, the biomarkers of heart failure (BNP and sST2) and renal injury (NGAL and cystatin C) at presentation were predictive of AKI. High serum levels of the biomarkers were associated with an elevated risk and more advanced stage of AKI. Regardless of the creatinine level, elevation of/C21² of the biomarkers...
higher than the cutoff values indicated a further rise in AKI risk. Combined biomarker ap-
proach may assist in risk stratification of AKI in patients with STEMI.

Introduction

Acute kidney injury (AKI) is well recognized as an important complication in patients with acute ST-segment elevation myocardial infarction (STEMI). Previous studies reported a high incidence of AKI in acute myocardial infarction (AMI), ranging from 10 to 27% [1–6], and the incidence could be as high as 50% if AMI is complicated by cardiogenic shock [7]. Development of AKI after AMI predicts short- [8] and long-term mortality [1–5, 9] and other major cardiovascular outcomes [10]. In an observational study of the Medicare patients, severe AKI (>1.0 mg/dL increase in serum creatinine) occurring after AMI was comparable in strength with other correlates of cardiovascular mortality, such as diabetes, cerebrovascular and peripheral vascular diseases [1]. Furthermore, even 0.1 mg/dl increase in serum creatinine level after AMI increases long-term risk of end stage renal disease (ESRD) [11]. Therefore, early detection of AKI in STEMI patients may assist in risk stratification and tailoring treatment during hospitalization and follow-up care.

Pathophysiologic interconnections between the heart and kidneys, the cardiorenal syn-
dromes (CRS), are defined as ‘disorders of the heart and kidneys whereby acute or chronic dys-
function in one organ may induce acute or chronic dysfunction of the other [12]’. Type 1 CRS, characterized by acute worsening of cardiac function leading to AKI, often complicates acute coronary syndrome (ACS) and acute decompensated heart failure (ADHF) [13–16]. Acute deterioration of cardiac function may set off a series of changes in neurohormonal and hemody-
namic factors leading to arterial underfilling and venous congestion. Inadequate renal perfusion, increased intra-abdominal pressure and passive kidney congestion may culminate in AKI [15–17]. In patients with cardiac diseases or undergoing cardiovascular surgery, new markers of renal dysfunction, such as neutrophil gelatinase-associated lipocalin (NGAL) [18–
21] and cystatin C [22–26], have emerged as early markers of AKI prior to any elevations of serum creatinine and have been shown to provide additional prognostic capacity in these set-
tings. Levels of traditional cardiac markers, such as natriuretic peptides [14, 27–29] and tropo-
nins [27, 30–32], rise in both cardiac and renal dysfunction, suggesting a bidirectional and reciprocal nature of the vicious circle of CRS.

ST2 (suppression of tumorigenicity 2), consisting of a trans-membrane ligand (ST2L) and a soluble form (sST2), is a member of the interleukin-1 receptor family and has been identified as a novel HF markers in response to mechanical stress [33–37]. As a decoy receptor of interleukin-33 (IL-33) that attenuates its cardioprotective properties [34], serum levels sST2 rise in various cardi-
diseases and have been shown to independently predict mortality and other adverse outcomes in HF [38–43] and MI [44–47]. Despite the well-established prognostic role, studies on the role of sST2 in CRS are sparse [48–50]. Compared with HF, few studies on CRS have addressed the de-
velopment of renal dysfunction in STEMI. This study aimed to combine the biomarkers of HF (BNP and sST2) and renal injury (NGAL and cystatin C) at presentation in the prediction of AKI in STEMI patients undergoing primary percutaneous coronary intervention (PCI).

Methods

Study population

From March 2010 to September 2013, patients sequentially admitted to Linkou Chang Gung Memorial Hospital in Taiwan with a diagnosis of STEMI were enrolled in this study. STEMI
was diagnosed according to the established criteria [51]. The inclusion criteria were patients with STEMI who presented within 12 hours of symptom onset and received primary coronary intervention (PCI). Exclusion criteria were as follows: STEMI patients presenting longer than 12 hours after symptom onset or not receiving primary PCI, history of renal failure requiring dialysis or with previous kidney transplantation, and unable to provide informed consents. The study protocol complied with the Declaration of Helsinki and was approved by the Institutional Regulation Board of Chang Gung Memorial Hospital, Taiwan (No. 101-5312B). Written informed consent was obtained from all patients.

Data collection and biomarker assay
All the STEMI patients were enrolled at presentation to the emergency department. The collected data included age, gender, body mass index (BMI), blood pressure, heart rate, smoking status, and underlying diseases such as coronary artery disease (CAD), diabetes, hypertension, heart failure and hyperlipidemia. The Killip criteria were used during physical examination to classify the severity of STEMI. Patients in Class I demonstrated no evidence of HF. Patients in Class II had findings consistent with mild to moderate HF. Patients in Class III demonstrated overt pulmonary edema and patients in Class IV were in cardiogenic shock [52]. The amount of contrast medium and the stent used in the PCI procedure were recorded. Coronary arteries with lesions of ≥50% diameter stenosis were regarded as diseased, and the number of diseased vessels was recorded. All the patients underwent echocardiography on admission and the left ventricular ejection fraction (LVEF) was acquired by modified Simpson’s method.

Blood samples were collected at presentation for basic laboratory tests, including troponin I, complete blood count, blood urea nitrogen (BUN), creatinine, sodium, potassium, and alanine transaminase. The blood samples were then centrifuged at 1,500 rpm for 5 minutes and stored at -80°C until thawed for assay for the biomarkers of HF (BNP and sST2) and renal injury (NGAL and cystatin C). BNP was assayed with the fluorescence immunoassay device Triage BNP Test (Biosite Diagnostics, San Diego, California). Serum sST2 concentrations were measured with the use of a high-sensitivity sandwich monoclonal immunoassay (Presage ST2 assay; Critical Diagnostics, San Diego, California). NGAL and cystatin C were measured by a single enzyme-linked immunosorbent assay (R&D Systems, Minneapolis, Minnesota).

Renal function assessment
The primary endpoint of this study was the development of AKI within 48 hours of presentation, according to the creatinine criteria of the Acute Kidney Injury Network (AKIN) [53]. Creatinine data were collected at presentation to the emergency department and within 48 hours of presentation. Admission estimated glomerular filtration rate (eGFR) was calculated using Modification of Diet in Renal Disease equation for Chinese patients [54]. The AKIN stage 1 is defined as an increase in serum creatinine of more than or equal to 0.3 mg/dL or increase to more than or equal to 1.5- to 2-fold from baseline. Stage 2 is increase in serum creatinine to more than 2- to 3-fold from baseline. Stage 3 is increase in serum creatinine to more than 3-fold from baseline (or serum creatinine of more than or equal to 4.0 mg/dL with an acute increase of at least 0.5 mg/dL).

Statistical analysis
Categorical variables were expressed as numbers and percentages and the chi-square test were used to compare variables between the study groups. Continuous variables were expressed as means ± standard deviation and compared with the Student’s t-test. Values of BNP, sST2, NGAL and cystatin C were reported as median (quartile 1—quartile 4) and compared with the
Mann-Whitney U test between the study groups. The Kruskal-Wallis test was used to compare continuous variables across multiple groups. The Spearman’s analysis was used to evaluate the correlation between the biomarkers. To determine the predicting factors of AKI, variables that were significant in the univariate logistic regression analysis were then incorporated into the multivariate logistic regression analysis. The receiver operation characteristic (ROC) analysis was used to evaluate the discrimination capacity of the biomarkers. A \( P \) value less than 0.05 was considered to be statistical significant. Data were analyzed with the SPSS version 19.0 (SPSS, Chicago, Illinois).

**Results**

A total of 189 patients presenting with STEMI from March 2010 to September 2013 were included in this study. Among the study patients, 37 (19.6%) developed AKI within 48 hours of admission. Table 1 shows the demographic and clinical characteristics of the AKI and non-AKI groups. There was no significant difference between the two groups in gender, BMI, mean arterial pressure, heart rate, LVEF, eGFR, prior CAD, HF, diabetes, hyperlipidemia, smoking status, number of diseased vessel on coronary angiography, stent deployment, contrast volume, use of medications, and serum levels of troponin I, sodium, potassium and alanine aminotransferase. Compared with the patients without AKI, patients in the AKI group were older (68.14 ± 12.64 years vs. 61.33 ± 13.86 years; \( P = 0.044 \)) and more frequently presented with Killip class \( \geq 2 \) (81.8% vs. 33.3%; \( P = 0.017 \)) and hypertension (81.8% vs. 49.3%; \( P = 0.044 \)). The AKI group also had higher mean levels of white blood cell (WBC) counts (12800 vs. 10449; \( P = 0.041 \)), BUN (33.53 vs. 17.89; \( P < 0.001 \)) and creatinine (2.00 vs. 1.03; \( P < 0.001 \)) and median levels of BNP (1225 vs. 139.5; \( P < 0.001 \)), sST2 (72.91 vs. 33.15; \( P < 0.001 \)), NGAL (238.5 vs. 86.95; \( P < 0.001 \)), and cystatin C (2.4 vs. 0.86; \( P = 0.007 \)), and lower levels of hemoglobin (12.69 vs. 14.18; \( P < 0.001 \)) and eGFR (50.13 vs. 90.68; \( P < 0.001 \)).

Table 2 shows the results of the univariate logistic regression analysis. Except for hypertension, all variables with a \( P \) value <0.05 in Table 1 remained significantly associated with AKI. However, in the multivariate analysis, no variable remained significant in predicting the development of AKI. As shown in Table 3, creatinine significantly correlated with the biomarkers of heart failure and renal injury. There was also significant correlation between BNP and sST2 (\( r = 0.325; P = 0.014 \)) and between NGAL and cystatin C (\( r = 0.545, P < 0.001 \)), but the correlation between the biomarkers of HF and renal injury was inconsistent. In Table 4, the results of the ROC analysis revealed that all the four biomarkers significantly discriminated the development of AKI (area under the ROC curves: BNP 0.86, sST2 0.74, NGAL 0.75, cystatin C 0.73; all \( P < 0.05 \)).

Table 1 illustrates the association of serum levels of the biomarkers and the AKIN stage. Serum levels of BNP, sST2, NGAL and cystatin C increased significantly across the spectrum of the AKIN stages. The risk of AKI also positively correlated with the serum levels of the biomarkers (Table 2). Using the creatine cutoff value of 1.24 mg/dL to group the STEMI patients into low and high risk of AKI, a further rise in risk was noted in the both groups if the patients presented with \( \geq 2 \) biomarkers elevated higher than the cutoff values derived from the ROC analysis (Table 3). This result implied that elevation of the biomarkers at presentation help discriminate the development of AKI within 48 hours, even in patients considered to be of low risk based on the creatine levels.

**Discussion**

In the current study, we aimed to combine the biomarkers of heart failure (BNP and sST2) and renal injury (NGAL and cystatin C) in diagnosis of AKI in patients with STEMI. The main findings of this study could be summarized as:
### Table 1. Baseline characteristics.

|                          | AKI (n = 36) | Non-AKI (n = 153) | P value |
|--------------------------|--------------|-------------------|---------|
| Age (years)              | 68.14 ± 12.64| 61.33 ± 13.86     | 0.01    |
| Male gender (%)          | 90.9         | 85.5              | 0.629   |
| Body mass index (kg/m²)  | 25.7 ± 3.79  | 25.21 ± 3.91      | 0.714   |
| Mean arterial pressure (mm Hg) | 116.87 ±140.67 | 97.84 ±22.9       | 0.424   |
| Heart rate (per minute)  | 83.31 ±26.6  | 74.32 ±17.09      | 0.163   |
| LVEF (%)                 | 52.3 ±21.31  | 57.04 ±11.85      | 0.178   |
| Killip class ≥ 2 (%)     | 81.8         | 33.3              | 0.017   |
| **Comorbidities (%)**    |              |                   |         |
| CAD history              | 36.4         | 15.9              | 0.107   |
| Heart failure            | 9.1          | 1.4               | 0.132   |
| Diabetes mellitus        | 54.5         | 27.5              | 0.073   |
| Hypertension             | 81.8         | 49.3              | 0.044   |
| Hyperlipidemia           | 52.4         | 70.4%             | 0.098   |
| Smoking                  | 54.5         | 60.9              | 0.691   |
| **Percutaneous coronary intervention** | | | 0.884 |
| Number of diseased vessel (%) | 45.5 | 42.6 |         |
| 2 vessels                | 36.4         | 32.4              |         |
| 3 vessels                | 18.2         | 25.0              |         |
| Stent deployment (%)     | 83.6         | 89.7              | 0.84    |
| Contrast volume (mL)     | 254.0 ±32.86 | 253.67±63.76      | 0.991   |
| **Laboratory tests, mean ± standard deviation** | | | |
| WBC (×10³/mm³)           | 12800±6433   | 10449±3137        | 0.041   |
| Hemoglobin (mg/dL)       | 12.69±2.09   | 14.18±2.06        | <0.001  |
| BUN (mg/dL)              | 33.53±17.82  | 17.89±13.79       | <0.001  |
| Creatinine (mg/dL)       | 2.00±1.35    | 1.03±0.74         | <0.001  |
| eGFR (min/mL)            | 50.13±28.69  | 90.68±28.48       | <0.001  |
| Sodium (mg/dL)           | 140.0±3.03315| 139.23±2.8        | 0.406   |
| Potassium (mg/dL)        | 4.04±0.65    | 3.87±0.38         | 0.423   |
| ALT (units/L)            | 54.67±44.94  | 45.4±30.6         | 0.511   |
| Troponin I (ng/mL)       | 7.65±25.33   | 4.88±6.46         | 0.169   |
| **Biomarkers of heart failure and renal injury, median (quartile 1—quartile 4)** | | | |
| BNP (pg/mL)              | 1225 (567.5–2120) | 139.5 (40.64–363.75) | <0.001 |
| sST2 (ng/mL)             | 72.91 (39.05–130.36) | 33.15 (25.55–62.34) | <0.001 |
| NGAL (n/mL)              | 238.5 (156.06–336.79) | 86.95 (82.64–15.45) | <0.001 |
| Cystatin C (mg/L)        | 2.4 (2.07–2.87) | 0.86 (0.63–1.22)  | 0.007   |
| **Medication (%)**       |              |                   |         |
| Diuretics                | 33.3         | 17.5              | 0.087   |
| DAPT                     | 90.9         | 95.7              | 0.503   |
| ACEI/ARB                 | 81.8         | 79.7              | 0.871   |
| Beta blocker             | 81.8         | 92.8              | 0.233   |
| Calcium channel block    | 19           | 10.5%             | 0.253   |
| Statin                   | 81.8         | 91.3              | 0.33    |

ACEI: angiotensin converting enzyme inhibitors; AKI: acute kidney injury; ALT: alanine transaminase; ARB: angiotensin receptor inhibitors; BNP: B-type natriuretic peptide; BUN, blood urea nitrogen; CAD: coronary artery disease; DAPT: dual antiplatelet therapy; eGFR: estimated glomerular filtration rate; LVEF: left ventricular ejection fraction; NGAL: neutrophil gelatinase-associated lipocalin; WBC: white blood cell.

doi:10.1371/journal.pone.0125282.t001
1. Serum levels of the four markers at presentation were predictive of AKI within 48 hours in STEMI patients undergoing primary PCI.

2. Serum levels of the biomarkers were correlated with an elevated risk and more advanced stage of AKI.

3. Regardless of the creatinine level on admission, elevation of \( \geq 2 \) of the biomarkers higher than the cutoff values significantly increased the risk of AKI.

Development of AKI after STEMI has been regarded as an important issue in patients with STEMI because of the increased in-hospital and long-term mortality and subsequent risk of ESRD [1–5, 9]. Patients hospitalized for STEMI are subjective to several complications and interventional procedures associated with AKI, such as cardiogenic shock, heart failure, cardiac catheterization, and coronary artery bypass surgery [7, 55–57]. Prior observational studies have explored the associated risk factors of AKI in these settings, including use of contrast agents, diabetes, previous kidney disease, hemodynamic instability, low cardiac output, and volume depletion [58–60]. Deterioration of renal function following acute alterations in cardiac function due to ADHF or ACS is classified as type 1 CRS [13, 15, 16]. Compared with HF, there are few reports in the literature on type 1 CRS in the setting of AMI. It has been proposed that cardiac dysfunction and hemodynamic perturbations could result in systemic underfilling and renal hypoperfusion, leading to further renal injury [16]. Neurohormonal activation,

| Table 2. Univariate analysis of predictors of acute kidney injury within 48 hours. |
|---------------------------------|-----------------|-----------------|-----------------|
|                                | Odds ratio      | 95% CI          | \( P \) value   |
| Age                            | 1.039           | 1.009–1.07      | 0.011           |
| Killip class \( \geq 2 \)      | 4.958           | 1.297–18.952    | 0.019           |
| eGFR                           | 0.952           | 0.931–0.974     | <0.001          |
| Hypertension                   | 4.623           | 0.932–23.018    | 0.061           |
| WBC                            | 1.001           | 1.001–1.002     | 0.099           |
| Hemoglobin                     | 0.712           | 0.587–0.863     | 0.001           |
| BUN                            | 1.069           | 1.025–1.115     | 0.002           |
| Creatinine                     | 3.701           | 1.794–7.632     | <0.001          |
| BNP                            | 1.002           | 1.001–1.004     | <0.001          |
| sST2                           | 1.004           | 1.001–1.007     | 0.006           |
| NGAL                           | 1.004           | 1.001–1.007     | 0.003           |
| Cystatin C                     | 1.002           | 1.001–1.003     | 0.001           |

BNP: B-type natriuretic peptide; BUN, blood urea nitrogen; eGFR: estimated glomerular filtration rate; NGAL: neutrophil gelatinase-associated lipocalin; WBC: white blood cell.

doi:10.1371/journal.pone.0125282.t002

| Table 3. Spearman’s correlation analysis of creatinine and the biomarkers of heart failure and renal injury. |
|---------------------------------|-----------------|-----------------|-----------------|
|                                | Creatinine      | BNP             | sST2            | NGAL            | Cystatin C       |
| Creatinine                     | 1.0             | 0.394 (\( P = 0.002 \)) | 0.357 (\( P <0.001 \)) | 0.376 (\( P <0.001 \)) | 0.261 (\( P = 0.002 \)) |
| BNP                            | 0.394 (\( P = 0.002 \)) | 1.0             | 0.325 (\( P = 0.014 \)) | 0.155 (\( P = 0.282 \)) | 0.302 (\( P = 0.14 \)) |
| sST2                           | 0.357 (\( P <0.001 \)) | 0.325 (\( P = 0.014 \)) | 1.0             | 0.243 (\( P = 0.055 \)) | 0.204 (\( P = 0.011 \)) |
| NGAL                           | 0.376 (\( P <0.001 \)) | 0.155 (\( P = 0.282 \)) | 0.184 (\( P = 0.079 \)) | 1.0             | 0.545 (\( P <0.001 \)) |
| Cystatin C                     | 0.261 (\( P <0.001 \)) | 0.302 (\( P = 0.14 \)) | 0.204 (\( P = 0.011 \)) | 0.545 (\( P <0.001 \)) | 1.0 |

BNP: B-type natriuretic peptide; NGAL: neutrophil gelatinase-associated lipocalin.

doi:10.1371/journal.pone.0125282.t003
Table 4. Receiver operating characteristic curve analysis of creatinine and the biomarkers of heart failure and renal dysfunction in predicting acute kidney injury.

|            | Cutoff value | AUC  | 95% CI  | P value | Sensitivity | Specificity | Youden index |
|------------|--------------|------|---------|---------|-------------|-------------|--------------|
| Creatinine | 1.24 mg/dL   | 0.89 | 0.83–0.94 | <0.001 | 0.76        | 0.91        | 0.67         |
| BNP        | 676 pg/mL    | 0.86 | 0.76–0.93 | <0.001 | 0.75        | 0.89        | 0.64         |
| sST2       | 50.77 ng/mL  | 0.74 | 0.64–0.79 | <0.001 | 0.71        | 0.72        | 0.43         |
| NGAL       | 133.7 ng/mL  | 0.75 | 0.64–0.85 | 0.006  | 0.7         | 0.77        | 0.47         |
| Cystatin C | 1.6 mg/L     | 0.73 | 0.63–0.81 | 0.016  | 0.79        | 0.69        | 0.48         |

AUC: area under the receiver operating characteristic curve; BNP: B-type natriuretic peptide; NGAL: neutrophil gelatinase-associated lipocalin.

doi:10.1371/journal.pone.0125282.t004

Fig 1. Serum levels of the biomarkers at presentation and the Acute Kidney Injury Network (AKIN) stages in patients developing acute kidney injury within 48 hours. Serum levels of BNP (A), sST2 (B), NGAL (C) and cystatin C (D) at presentation increased significantly across the spectrum of the AKIN stages within 48 hours.

doi:10.1371/journal.pone.0125282.g001
Fig 2. Serum levels of the biomarkers at presentation and the risk of developing acute kidney injury within 48 hours. The risk of developing acute kidney injury at 48 hours increased significantly as serum levels of biomarkers rose at presentation.

doi:10.1371/journal.pone.0125282.g002

Fig 3. Number of biomarkers elevated higher than the cutoff values and the risk of developing acute kidney injury within 48 hours: (A) patients with creatinine levels <1.24 mg/dL; (B) patients with creatinine level ≥1.24 mg/dL. Regardless of the creatinine level on admission, elevation of ≥2 of the biomarkers higher than the cutoff values provided incremental value in risk stratification of acute kidney injury.

doi:10.1371/journal.pone.0125282.g003
hypothalamic-pituitary stress reaction, and inflammation have also been shown to contribute to type 1 CRS [16]. However, there is increasing evidence that it may be venous congestion rather than arterial underfilling that is associated decreasing renal blood flow and worsening renal function [61–64]. Diastolic LV dysfunction, the earliest change seen after coronary occlusion [65] results in elevated LV filling pressure and central venous pressure. As demonstrated in an early animal model by Winton et al., temporary elevation of central venous pressure can be transmitted back to the renal veins and result in direct renal dysfunction [66]. A more recent study by Danman et al. showed that increased central venous pressure is associated with impaired renal function and mortality in patients with cardiovascular diseases [64].

BNP was predictive of AKI in the current analysis, consistent with the result of recent studies. Akagul et al. reported that BNP was associated with AKI and 6-month all-cause mortality in STEMI patients [67]. In a biomarker analysis of the HORIZONS-AMI trial, Guerchicoff et al. found that BNP levels were consistently higher in the AKI group at baseline, hospital discharge, 30-day follow-up, and 1-year follow-up [68]. BNP, a cardiac hormone released by ventricular cardiomyocytes, elevates in both systolic and diastolic HF in response to ventricular dysfunction and increased myocardial stress [69, 70]. Given its association with capillary wedge pressure and venous congestion, BNP has been demonstrated to be an indirect marker for worsening renal function in ADHF [71, 72]. In patients with AMI, increased filling pressure and ventricular wall stress secondary to myocardial ischemia may be one of the factors behind the elevation of serum BNP levels [73, 74]. We hypothesized that increased BNP levels indicated elevation of central venous pressure and passive renal congestion and could also serve as an indirect marker of AKI in AMI.

The current analysis may be one of the earliest studies to examine the role of sST2 in AKI in patients with STEMI. sST2 is a novel cardiac biomarker complementary to the natriuretic peptides in the risk prediction of HF hospitalization and death [38, 42, 75]. The association between sST2 and AKI discovered in our STEMI cohort may provide another insight into the pathogenesis of type 1 CRS. As a marker of mechanical stretch similar to the natriuretic peptides, sST2 has been demonstrated to significantly correlated with hemodynamics, LVEF, disease severity and adverse remodeling in AMI [44, 46, 47, 76] and predict pulmonary artery pressure, right ventricular hypokinesis and jugular venous distension in ADHF [41]. In a cohort of 3,450 participants from the Framingham Heart Study, serum sST2 concentration correlated significantly with age, diabetes and inflammation [77], which are also regarded as classic risk factors of AKI during acute illness [78]. The association between sST2 and diabetes, hypertension and inflammatory markers not only suggests the role of ST2 as a cardiometabolic marker but implicates its potential in predicting AKI and CRS in acute cardiac events. Importantly, sST2 has been considered to reflect immune cell activation and cell signaling in progressive HF [17]. As a decoy receptor of IL-33, sST2 attenuates cardioprotective effects provided by IL-33 [34], potentially further causing cardiac dysfunction, hemodynamic instability and potentiating the risk of renal injury. Furthermore, serum levels of sST2 have been shown to significantly correlate with neurohormonal activation, as indicated by its association with norepinephrine and aldosterone levels in patient with AMI [76]. On the contrary, however, a recent study in ADHF by Legrand et al. [49] reported lack of association between sST2 and worsening of renal function in patients with ADHF. The difference in study population may be the reason for the inconsistent results. To achieve a better understanding of the association between sST2 and CRS, further study is warranted to delineate IL-33/ST2 pathway in kidney injury in various cardiac events.

Our finding that the biomarkers of renal injury, NGAL and cystatin C, were predictive of AKI is consistent with the results of previous work. Established as biomarkers of AKI, both NGAL and cystatin C have been well explored in cardiovascular diseases beyond confines of nephrology.
In a study by Lindberg et al., plasma NGAL independently predicted all-cause mortality and MACE in STEMI patients treated with primary PCI [79]. In that study, higher levels of plasma NGAL was significantly associated with lower eGFR. In patients with acute and chronic HF, serum NGAL has been supposed to be a novel, sensitive marker of worsening renal function [80, 81]. Similarly, cystatin C has also been demonstrated as an early marker of AKI in patients with ADHF [82] and AMI [6, 26] and those admitted to the coronary care unit [83]. Furthermore, an additive prognostic value of cystatin C was found in patients with AMI [26] and ADHF [82].

Given the increased morbidity and mortality associated with the development of AKI in patients with acute illness, there are high demands to establish an ideal biomarker in AKI, such as organ specific, highly sensitive for indicating renal injury, unaffected by other biomarkers, helpful in differential diagnosis and monitoring disease course and response to treatment [84]. Because such an ideal biomarker is probably not available to date, a multi-marker model has been proposed for AKI for risk prediction, early diagnosis and even to give deep insight into pathophysiologic mechanisms. Just as the multi-marker panels used in HF and MI, we hypothesized that combined biomarkers of HF and renal injury may provide incremental diagnostic values and improve risk stratification in STEMI patients developing AKI. Although each of the four biomarkers was predictive of AKI in the current study, however, confounding factors such as age, gender, body habitus and comorbidities may affect the levels of these markers independent of the cardiorenal axis. As a consequence, the specificity of these biomarkers may be somewhat limited. Therefore, we analyzed two classes of biomarkers that potentially play a role in CRS and found that this combined approach may provide additive values in AKI risk stratification, even in the patients with low levels of serum creatinine at admission. Interestingly, while renal function correlated significantly with the biomarkers of HF and renal injury, the correlation between biomarkers of HF and renal injury was inconsistent. A possible explanation of this observation is that impaired renal function in STEMI patients may arise more from hemodynamic alterations and venous congestion than from direct insult to kidney structure. Further investigation of the observed heart-kidney interface in CRS may provide better understanding of the bidirectional nature of pathophysiologic crosstalk in this vicious cycle.

Limitations

This current study has several limitations. This was a single center study with a small sample number. Along with the few adverse events, we could not provide outcome data such as dialysis or survival. In addition to the biomarkers, there were several factors significantly associated with AKI in this study, such as age, Killip class, renal function, WBC count, and hemoglobin level. Despite the significance in predicting AKI in the univariate analysis, none of these parameters remained statistically significant in the adjusted model. We used serum for NGAL and cystatin C assay but not urine samples, while some suggested that urine NGAL and cystatin C would be more specific to renal tubular injury and dysfunction [49]. It remains to be determined whether analysis with urine biomarkers provides comparable results. Furthermore, the serum levels of biomarkers were measured only at presentation for risk stratification of AKI but not analyzed serially for early diagnosis. All the patients in this study presented with STEMI, and it is unclear whether the results could be generalized to other cardiovascular diseases. Large, prospective multicenter studies are warranted to validate our data and compare it with other exiting biomarkers and parameters in a multi-marker model.

Conclusions

In this single center study, we found that the biomarkers of heart failure (BNP and sST2) and renal injury (NGAL and cystatin C) at presentation were predictive of AKI within 48 hours in
patients with STEMI undergoing primary PCI. High serum levels of the biomarkers were associated with an elevated risk and more advanced stage of AKI. Elevation of ≥ 2 of the biomarkers higher than the cutoff values indicated a further rise in the risk of AKI, even in the patients with low creatinine levels on admission. Therefore, combination of two classes of the biomarkers that potentially play a role in CRS may provide additive values in AKI risk stratification in patients with STEMI.

Author Contributions
Conceived and designed the experiments: PHC. Performed the experiments: YCT CHC YCC. Analyzed the data: YCT CHC YCC PHC. Contributed reagents/materials/analysis tools: YCC PHC. Wrote the paper: YCT PHC.

References
1. Parikh CR, Coca SG, Wang Y, Masoudi FA, Krumholz HM. Long-term prognosis of acute kidney injury after acute myocardial infarction. Arch Intern Med. 2008; 168(9):987–95. doi: 10.1001/archinte.168.9.987 PMID: 18474763
2. Goldberg A, Hammerman H, Petcherski S, Zdorovyak A, Yalonetsky S, Kapeliovich M, et al. Inhospital and 1-year mortality of patients who develop worsening renal function following acute ST-elevation myocardial infarction. Am Heart J. 2005; 150(2):330–7. PMID: 16086939
3. Bruetto RG, Rodrigues FB, Torres US, Otaviano AP, Zanetta DM, Burdmann EA. Renal function at hospital admission and mortality due to acute kidney injury after myocardial infarction. PLoS One. 2012; 7(4):e35496. doi: 10.1371/journal.pone.0035496 PMID: 22539974
4. Amin AP, Spertus JA, Reid KJ, Lan X, Buchanan DM, Decker C, et al. The prognostic importance of worsening renal function during an acute myocardial infarction on long-term mortality. Am Heart J. 2010; 160(6):1065–71. doi: 10.1016/j.ahj.2010.08.007 PMID: 21464669
5. Latchamsetty R, Fang J, Kline-Rogers E, Mukherjee D, Otten RF, LaBounty TM, et al. Prognostic value of transient and sustained increase in in-hospital creatinine on outcomes of patients admitted with acute coronary syndrome. Am J Cardiol. 2007; 99(7):939–42. PMID: 17398188
6. Hsiao P-G, Hsieh C-A, Yeh C-F, Wu H-H, Shiu T-F, Chen Y-C, et al. Early prediction of acute kidney injury in patients with acute myocardial injury. J Crit Care. 2012; 27(5):525. e1-7. doi: 10.1016/j.jcrc.2012.05.003 PMID: 22762928
7. Marenzi G, Assanelli E, Campodonico J, De Metrio M, Lauri G, Marana I, et al. Acute kidney injury in ST-segment elevation acute myocardial infarction complicated by cardiogenic shock at admission. Crit Care Med. 2010; 38(2):438–44. doi: 10.1097/CCM.0b013e181b5eb3b PMID: 19789449
8. Fox CS, Muntnier P, Chen AY, Alexander KP, Roe MT, Wiviott SD. Short-term outcomes of acute myocardial infarction in patients with acute kidney injury: a report from the national cardiovascular data registry. Circulation. 2012; 125(3):497–504. doi: 10.1161/CIRCULATIONAHA.111.039909 PMID: 22179533
9. Tsai H-S, Chen Y-C, Chu P-H. The influence of acute kidney injury on acute cardiovascular disease. Acta Cardiol Sin. 2014; 30(2):93–7.
10. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau J-L, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004; 351(13):1285–95. PMID: 15385655
11. Newsome BB, Warnock DG, McClellan WM, Herzog CA, Kiefe CI, Eggers PW, et al. Long-term risk of mortality and end-stage renal disease among the elderly after small increases in serum creatinine level during hospitalization for acute myocardial infarction. Arch Intern Med. 2008; 168(6):609–16. doi: 10.1001/archinte.168.6.609 PMID: 18362253
12. Ronco C, McCullough P, Anker SD, Anand I, Aspromonte N, Bagshaw SM, et al. Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative. Eur Heart J. 2010; 31(6):703–11. doi: 10.1093/eurheartj/ehp97 PMID: 20037146
13. Ronco C, McCullough PA, Anker SD, Anand I, Aspromonte N, Bagshaw SM, et al. Cardiorenal syndromes: an executive summary from the consensus conference of the Acute Dialysis Quality Initiative (ADQI). Contrib Nephrol. 2010; 165:54–67. doi: 10.1159/000313743 PMID: 20427956
14. Tang WW, Mullens W. Cardiorenal syndrome in decompensated heart failure. Heart. 2010; 96(4):255–60. doi: 10.1136/hrt.2009.166256 PMID: 19401280
15. Ismail Y, Kasmikha Z, Green HL, McCullough PA. Cardio-Renal Syndrome Type 1: Epidemiology, Pathophysiology, and Treatment. Semin Nephrol. 2012; 32(1):18–25. doi: 10.1016/j.semnephrol.2011.11.003 PMID: 22365158

16. Ronco C, Cicoira M, McCullough PA. Cardiorenal Syndrome Type 1. J Am Coll Cardiol. 2012; 60(12):1031–42. doi: 10.1016/j.jacc.2012.01.077 PMID: 22840531

17. McCullough PA, Kellum JA, Haase M, Mueller C, Damman K, Murray PT, et al. Pathophysiology of the cardiorenal syndromes: executive summary from the eleventh consensus conference of the Acute Dialysis Quality Initiative (ADQI). Contrib Nephrol. 2013; 182:82–98. doi: 10.1159/000349966 PMID: 23689657

18. Mishra J, Dent C, Tarabishi R, Mitsnifes MM, Ma Q, Kelly C, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet. 2005; 365(9466):1231–8. PMID: 15811456

19. Haase-Fielitz A, Bellomo R, Devarajan P, Story D, Matalanis G, Dragun D, et al. Novel and conventional serum biomarkers predicting acute kidney injury in adult cardiac surgery—A prospective cohort study. Crit Care Med. 2009; 37(2):553–60. doi: 10.1097/CCM.0b013e318195846e PMID: 19114878

20. Prabhu A, Sujatha D, Ninan B, Vijayakalshmi M. Neutrophil gelatinase associated lipocalin as a biomarker for acute kidney injury in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass. Ann Vasc Surg. 2010; 24(4):525–31. doi: 10.1016/j.avsg.2010.01.001 PMID: 20363104

21. Haase M, Devarajan P, Haase-Fielitz A, Bellomo R, Cruz DN, Wagener G, et al. The Outcome of Neutrophil Gelatinase-Associated Lipocalin-Positive Subclinical Acute Kidney Injury A Multicenter Pooled Analysis of Prospective Studies. J Am Coll Cardiol. 2011; 57(17):1752–61. doi: 10.1016/j.jacc.2010.11.051 PMID: 21511111

22. Zhu J, Yin R, Wu H, Yi J, Luo L, Dong G, et al. Cystatin C as a reliable marker of renal function following heart valve replacement surgery with cardiopulmonary bypass. Clin Chim Acta. 2006; 374(1):116–21.

23. Wald R, Liangos O, Perianayagam MC, Kolyada A, Herget-Rosenthal S, Moritz A. Early postoperative serum cystatin C and acute kidney injury after cardiopulmonary bypass. Clin J Am Soc Nephrol. 2010; 5(8):1373–9. doi: 10.2215/CJN.06350909 PMID: 20522534

24. Silva D, Cortez-Dias N, Jorge C, Marques JS, Carrilho-Ferreira P, Magalhães A, et al. Cystatin C as prognostic biomarker in ST-segment elevation acute myocardial infarction. Am J Cardiol. 2012; 109(10):1431–8. doi: 10.1016/j.amjcard.2012.01.356 PMID: 22356795

25. Kiessling A-H, Dietz J, Reyher C, Stock UA, Beiras-Fernandez A, Moritz A. Early postoperative serum cystatin C predicts severe acute kidney injury following cardiac surgery: a post-hoc analysis of a randomized controlled trial. J Cardiothorac Surg. 2014; 9(1):10.

26. Fouad M, Boraei M. Cystatin C as an early marker of acute kidney injury and predictor of mortality in the intensive care unit after acute myocardial infarction. Arab J Nephrol Transplant. 2013; 6(1):21–6. PMID: 23282229

27. Palazzuoli A, Masson S, Ronco C, Maisel A. Clinical relevance of biomarkers in heart failure and cardiorenal syndrome: the role of natriuretic peptides and troponin. Heart Fail Rev. 2014; 19(2):267–84. doi: 10.1007/s10741-013-9391-x PMID: 23563622

28. Januzzi JL Jr, Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG, et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol. 2005; 95(8):1373–9. doi: 10.1016/j.amjcard.2005.05.039 PMID: 16938661

29. Fitzgerald RL, Maisel AS, Clopton P, Beede J, Isakson SR, Hernandez-Arce I, et al. Correlation and Prognostic Utility of B-Type Natriuretic Peptide and Its Amino-Terminal Fragment in Patients With Chronic Kidney Disease. Am J Clin Pathol. 2006; 126(4):506–12. PMID: 16938661

30. Freda BJ, Tang WW, Van Lente F, Peacock WF, Francis GS. Cardiac troponins in renal insufficiency: view and clinical implications. J Am Coll Cardiol. 2002; 40(12):2065–71. PMID: 12505215

31. Aviles RJ, Askari AT, Lindahl B, Wallentin L, Jia G, Ohman EM, et al. Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. N Engl J Med. 2002; 346(26):2047–52. PMID: 12087140

32. Apple FS, Murakami MM, Pearce LA, Herzog CA. Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. Circulation. 2002; 106(23):2941–5. PMID: 12460876

33. Weinberg EO, Shimo M, De Keulenaer GW, MacGillivray C, Tominaga S-I, Solomon SD, et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation. 2002; 106(23):2961–6. PMID: 12460879

34. Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest. 2007; 117(6):1538–49. PMID: 17492053
35. Kakkar R, Lee RT. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov. 2008; 7(10):827–40. doi: 10.1038/nrd2660 PMID: 18287286

36. Januzzi JL Jr. ST2 as a cardiovascular risk biomarker: from the bench to the bedside. J Cardiovasc Transl Res. 2013; 6(4):493–500. doi: 10.1007/s12265-013-9459-y PMID: 23558647

37. Tung Y-C, Chu P-H. Soluble ST2: A novel prognostic biomarker of heart failure. Acta Cardiol Sin. 2014; 30(5):501–3.

38. Ky B, French B, McCloskey K, Rame JE, McIntosh E, Shahi P, et al. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail. 2011; 4(2):180–7. doi: 10.1161/CIRCHEARTFAILURE.110.958223 PMID: 21178018

39. Zethelius B, Berglund L, Sundström J, Ingelsson E, Basu S, Larsson A, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med. 2008; 358(20):2107–16. doi: 10.1056/NEJMoa0707064 PMID: 18480203

40. Januzzi JL, Peacock WF, Maisel AS, Chae CU, Jesse RL, Baggish AL, et al. Measurement of the Interleukin Family Member ST2 in Patients With Acute Dyspnea Results From the PRIDE (Pro-Bran Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) Study. J Am Coll Cardiol. 2007; 50(7):607–13. PMID: 17692745

41. Shah RV, Chen-Tournoux AA, Picard MH, van Kimmenade RR, Januzzi JL. Serum levels of the interleukin-1 receptor family member ST2, cardiac structure and function, and long-term mortality in patients with acute dyspnea. Circ Heart Fail. 2009; 2(4):311–9. doi: 10.1161/CIRCHEARTFAILURE.108.833707 PMID: 19808354

42. Mueller T, Dieplinger B, Gegenhuber A, Pechl W, Pacher R, Haltmayer M. Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Clin Chem. 2008; 54(4):752–6. doi: 10.1373/clinchem.2007.096560 PMID: 18375488

43. Broch K, Ueland T, Nymo SH, Kjekshus J, Hulthe J, Muntendam P, et al. Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology. Eur J Heart Fail. 2012; 14(3):268–77. doi: 10.1036/eurjhf/hfs006 PMID: 22302661

44. Dhillon OS, Narayan HK, Quinn PA, Squire IB, Davies JE, Wallentin L, et al. Interleukin 33 and ST2 in non-ST-elevation myocardial infarction: comparison with Global Registry of Acute Coronary Events Risk Scoring and NT-proBNP. Am Heart J. 2011; 161(6):1163–70. doi: 10.1016/j.ahj.2011.03.025 PMID: 21641364

45. Eggers KM, Armstrong PW, Califf RM, Simoons ML, Venge P, Wallentin L, et al. ST2 and mortality in non-ST-segment elevation acute coronary syndrome. Am Heart J. 2010; 159(5):788–94. doi: 10.1016/j.ahj.2010.02.022 PMID: 20435187

46. Sabatine MS, Morrow DA, Higgins LJ, MacGillivray C, Guo W, Bode C, et al. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation. 2008; 117(15):1936–44. doi: 10.1161/CIRCULATIONAHA.107.728022 PMID: 18378613

47. Shimp M, Morrow DA, Weinberg EO, Sabatine MS, Murphy SA, Antman EM, et al. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation. 2004; 109(18):2186–90. PMID: 15117853

48. Bayes-Genis A, Zamora E, de Antonio M, Galán A, Vila J, Urrutia A, et al. Soluble ST2 serum concentration and renal function in heart failure. J Card Fail. 2013; 19(11):768–75. doi: 10.1016/j.cardfail.2013.09.005 PMID: 24263122

49. Legrand M, De Berardinis B, Gaggin HK, Magrini L, Belcher A, Zanca B, et al. Evidence of uncoupling between renal dysfunction and injury in cardiorenal syndrome: insights from the BIONICS Study. PloS One. 2014; 9(11):e112313. doi: 10.1371/journal.pone.0112313 PMID: 25386851

50. De Berardinis B, Gaggin HK, Magrini L, Belcher A, Zanca B, Femia A, et al. Comparison between admission natriuretic peptides, NGAL and sST2 testing for the prediction of worsening renal function in patients with acutely decompensated heart failure. Clin Chem Lab Med. 2014. doi: 10.1515/cclm-2014-0191

51. Kushner FG, Hand M, Smith SC, King SB, Anderson JL, Antman EM, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2009; 53(23):2205–41. doi: 10.1016/j.jacc.2009.10.015 PMID: 19942100

52. Khot UN, Jia G, Moliterno DJ, Lincoff AM, Khot MB, Harrington RA, et al. Prognostic importance of physical examination for heart failure in non-ST-elevation acute coronary syndromes: the enduring value of Killip classification. JAMA. 2003; 290(16):2174–81. PMID: 14570953
74. Sabatine MS, Morrow DA, de Lemos JA, Desai MY, Tanasijevic M, et al. Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. J Am Coll Cardiol. 2004; 44(10):1988–95. PMID: 15542281

75. Weinberg EO, Shimoto M, Hurwitz S, Tominaga S-I, Rouleau J-L, Lee RT. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation. 2003; 107(5):721–6. PMID: 12578875

76. Weir RA, Miller AM, Murphy GE, Clements S, Steedman T, Connell JM, et al. Serum Soluble ST2A Potential Novel Mediator in Left Ventricular and Infarct Remodeling After Acute Myocardial Infarction. J Am Coll Cardiology. 2010; 55(3):243–50. doi: 10.1016/j.jacc.2009.08.047 PMID: 20117403

77. Coglianese EE, Larson MG, Vasan RS, Ho JE, Ghorbani A, McCabe EL, et al. Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study. Clin Chem. 2012; 58(12):1673–81. doi: 10.1373/clinchem.2012.192153 PMID: 23065477

78. Leblanc M, Kellum JA, Gibney RTN, Lieberthal W, Tumlin J, Mehta R. Risk factors for acute renal failure: inherent and modifiable risks. Curr Opin Crit Care. 2005; 11(6):533–6. PMID: 16292055

79. Lindberg S, Pedersen SH, Mogelvang R, Jensen JS, Flyvbjerg A, Galatius S, et al. Prognostic utility of neutrophil gelatinase-associated lipocalin in predicting mortality and cardiovascular events in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. J Am Coll Cardiol. 2012; 60(4):339–45. doi: 10.1016/j.jacc.2012.04.017 PMID: 22813613

80. Poniatowski B, Malyszko J, Bachorzewska-Gajewska H, Malyszko JS, Dobrzycki S. Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in patients with chronic heart failure and coronary artery disease. Kidney Blood Press Res. 2008; 32(2):77–80.

81. Aghel A, Shrestha K, Mullens W, Borowski A, Tang WW. Serum neutrophil gelatinase-associated lipocalin (NGAL) in predicting worsening renal function in acute decompensated heart failure. J Card Fail. 2010; 16(1):49–54. doi: 10.1016/j.cardfail.2009.07.003 PMID: 20123318

82. Lassus JP, Nieminen MS, Peuhkurinen K, Pulkki K, Siirola-Waris K, Sund R, et al. Markers of renal function and acute kidney injury in acute heart failure: definitions and impact on outcomes of the cardiorenal syndrome. Eur Heart J. 2010; 31(22):2791–8. doi: 10.1093/eurheartj/ehq293 PMID: 20801926

83. Chen TH, Chang CH, Lin CY, Jeng CC, Chang MY, Tian YC, et al. Acute kidney injury biomarkers for patients in a coronary care unit: a prospective cohort study. PloS One. 2012; 7(2):e32328. doi: 10.1371/journal.pone.0032328 PMID: 22384218

84. Urbschat A, Obermüller N, Haferkamp A. Biomarkers of kidney injury. Biomarkers. 2011; 16 Suppl 1: S22–30. doi: 10.3109/1354750X.2011.587129 PMID: 21707441